Business Context and Reporting Period
This Form 6-K filing by Mainz Biomed N.V. (noted as Quantum Cyber N.V. in metadata) covers the month of August 2025. The report details the entry into material agreements regarding a private securities offering.
Key Financial Metrics
- Gross Proceeds: Approximately $3,000,000 from the sale of 2,222,222 pre-funded units.
- Offering Price: $1.35 per pre-funded unit (net of a $0.001 nominal exercise price).
- Placement Fees: 7% of gross proceeds plus a fixed fee of $85,000 paid to Maxim Group, LLC.
- Capital Structure Impact: Issuance of pre-funded warrants (exercisable at $0.001) and ordinary warrants (exercisable at $1.35, expiring in five years).
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics outside of the specific transaction details.
Material Changes
The primary material change is the completion of a capital raise on August 5, 2025. The company entered into a Securities Purchase Agreement (SPA) with an institutional investor and a Placement Agency Agreement with Maxim Group, LLC. This transaction increases the company's cash position by approximately $3 million before expenses.
Outlook, Risks, and Management Commentary
Management commentary is limited to the description of the transaction terms. The ordinary warrants include anti-dilution provisions for stock dividends and splits. The filing incorporates by reference the Registration Statement on Form F-3 (File No. 333-269091). No specific forward-looking guidance, risk factors, or contingencies beyond standard agreement representations are detailed in this specific text.
Investor Verification Checklist
- Verify the final net proceeds after deducting the 7% placement fee and the $85,000 fixed fee.
- Confirm the exact number of ordinary shares issued upon immediate exercise of the pre-funded warrants.
- Review the full Registration Statement on Form F-1 (no. 333-289095) for detailed warrant terms and anti-dilution mechanics.
- Check the company's updated capitalization table to assess dilution impact on existing shareholders.